{"id":"brimonidine-tartrate-gel","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Brimonidine tartrate gel is an alpha-2 adrenergic agonist that decreases the production of norepinephrine, a neurotransmitter that can cause blood vessels to dilate and increase blood flow to the skin. By reducing norepinephrine levels, brimonidine tartrate gel helps to decrease redness and swelling in the skin, making it a useful treatment for conditions such as rosacea.","oneSentence":"Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:15.559Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of erythema associated with rosacea"}]},"trialDetails":[{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT07082764","phase":"PHASE2","title":"Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Tarian Pharma","startDate":"2025-09-01","conditions":"Chemotherapy Induced Peripheral Neuropathy","enrollment":30},{"nctId":"NCT06818058","phase":"PHASE2","title":"TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis","status":"RECRUITING","sponsor":"Tarian Pharma","startDate":"2025-01-20","conditions":"EGFR Inhibitor-associated Rash","enrollment":60},{"nctId":"NCT03508869","phase":"NA","title":"Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea","status":"TERMINATED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2016-09-27","conditions":"Erythema and Flushing Associated With Rosacea","enrollment":5},{"nctId":"NCT01659853","phase":"PHASE3","title":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-09","conditions":"Erythema, Rosacea","enrollment":70},{"nctId":"NCT02249065","phase":"PHASE4","title":"Mirvaso in Use Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-09","conditions":"Rosacea","enrollment":205},{"nctId":"NCT05401422","phase":"NA","title":"Brimonidine in Rosacea","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-05-25","conditions":"Rosacea","enrollment":45},{"nctId":"NCT02385240","phase":"PHASE3","title":"Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-03","conditions":"Rosacea","enrollment":552},{"nctId":"NCT01885000","phase":"PHASE3","title":"Patient-Reported Outcome Of Facial Erythema (PROOF)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-07-01","conditions":"Rosacea, Erythema","enrollment":92},{"nctId":"NCT00697541","phase":"PHASE2","title":"Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-05","conditions":"Erythematous Rosacea","enrollment":20},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT03497442","phase":"EARLY_PHASE1","title":"Treatment of Asian Flushing Syndrome With Topical Alpha Agonists","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-07-12","conditions":"Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency","enrollment":20},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT02289352","phase":"PHASE3","title":"Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-07","conditions":"Rosacea","enrollment":462},{"nctId":"NCT02764411","phase":"PHASE3","title":"Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2016-06","conditions":"Capillary Malformations","enrollment":6},{"nctId":"NCT03173365","phase":"PHASE2","title":"The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2017-07-10","conditions":"Hand-foot Syndrome","enrollment":2},{"nctId":"NCT03048058","phase":"PHASE4","title":"Internet Surveys and Their Impact on Adherence for Rosacea","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05-05","conditions":"Rosacea","enrollment":20},{"nctId":"NCT02856919","phase":"PHASE4","title":"A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.","status":"COMPLETED","sponsor":"Galderma Brasil Ltda.","startDate":"2016-06-13","conditions":"Chronic Persistent Vascular Facial Erythema","enrollment":101},{"nctId":"NCT02568111","phase":"PHASE4","title":"Brimonidine Tartrate for the Treatment of Injection Related Erythema","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2016-02","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":""},{"nctId":"NCT02147691","phase":"PHASE4","title":"Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2014-05","conditions":"Acne Rosacea","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Brimonidine Tartrate Gel","genericName":"Brimonidine Tartrate Gel","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine tartrate gel works by reducing the amount of norepinephrine in the body, which helps to decrease redness and swelling in the skin. Used for Treatment of erythema associated with rosacea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}